Although both in vivo and in vitro studies [38,39,40] have shown that ADT upregulates PSMA expression, with enhanced PSMA expression demonstrated in 55% of patients with high-grade and advanced PCa treated with ADT, it appears that PSMA expression rises with a short duration of ADT and declines with a longer duration of therapy [41,42]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.